A robust optimization approach to cancer treatment under toxicity uncertainty

Junfeng Zhu, Hamidreza Badri, Kevin Z Leder

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The design of optimal protocols plays an important role in cancer treatment. However, in clinical applications, the outcomes under the optimal protocols are sensitive to variations of parameter settings such as drug effects and the attributes of age, weight, and health conditions in human subjects. One approach to overcoming this challenge is to formulate the problem of finding an optimal treatment protocol as a robust optimization problem (ROP) that takes parameter uncertainty into account. In this chapter, we describe a method to model toxicity uncertainty. We then apply a mixed integer ROP to derive the optimal protocols that minimize the cumulative tumor size. While our method may be applied to other cancers, in this work we focus on the treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKI). For simplicity, we focus on one particular mode of toxicity arising from TKI therapy, low blood cell counts, in particular low absolute neutrophil count (ANC). We develop optimization methods for locating optimal treatment protocols assuming that the rate of decrease of ANC varies within a given interval. We further investigated the relationship between parameter uncertainty and optimal protocols. Our results suggest that the dosing schedule can significantly reduce tumor size without recurrence in 360 weeks while insuring that toxicity constraints are satisfied for all realizations of uncertain parameters.

Original languageEnglish (US)
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages297-331
Number of pages35
DOIs
StatePublished - Jan 1 2018

Publication series

NameMethods in Molecular Biology
Volume1711
ISSN (Print)1064-3745

Fingerprint

Uncertainty
Clinical Protocols
Protein-Tyrosine Kinases
Neoplasms
Neutrophils
Blood Cell Count
Therapeutics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Appointments and Schedules
Weights and Measures
Recurrence
Health
Pharmaceutical Preparations

Keywords

  • Cancer treatment
  • Mixed integer optimization
  • Robust optimization
  • Toxicity uncertainty

PubMed: MeSH publication types

  • Journal Article
  • Research Support, U.S. Gov't, Non-P.H.S.

Cite this

Zhu, J., Badri, H., & Leder, K. Z. (2018). A robust optimization approach to cancer treatment under toxicity uncertainty. In Methods in Molecular Biology (pp. 297-331). (Methods in Molecular Biology; Vol. 1711). Humana Press Inc.. https://doi.org/10.1007/978-1-4939-7493-1_15

A robust optimization approach to cancer treatment under toxicity uncertainty. / Zhu, Junfeng; Badri, Hamidreza; Leder, Kevin Z.

Methods in Molecular Biology. Humana Press Inc., 2018. p. 297-331 (Methods in Molecular Biology; Vol. 1711).

Research output: Chapter in Book/Report/Conference proceedingChapter

Zhu, J, Badri, H & Leder, KZ 2018, A robust optimization approach to cancer treatment under toxicity uncertainty. in Methods in Molecular Biology. Methods in Molecular Biology, vol. 1711, Humana Press Inc., pp. 297-331. https://doi.org/10.1007/978-1-4939-7493-1_15
Zhu J, Badri H, Leder KZ. A robust optimization approach to cancer treatment under toxicity uncertainty. In Methods in Molecular Biology. Humana Press Inc. 2018. p. 297-331. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-4939-7493-1_15
Zhu, Junfeng ; Badri, Hamidreza ; Leder, Kevin Z. / A robust optimization approach to cancer treatment under toxicity uncertainty. Methods in Molecular Biology. Humana Press Inc., 2018. pp. 297-331 (Methods in Molecular Biology).
@inbook{436ebc57f4924cceb8cc43227750559b,
title = "A robust optimization approach to cancer treatment under toxicity uncertainty",
abstract = "The design of optimal protocols plays an important role in cancer treatment. However, in clinical applications, the outcomes under the optimal protocols are sensitive to variations of parameter settings such as drug effects and the attributes of age, weight, and health conditions in human subjects. One approach to overcoming this challenge is to formulate the problem of finding an optimal treatment protocol as a robust optimization problem (ROP) that takes parameter uncertainty into account. In this chapter, we describe a method to model toxicity uncertainty. We then apply a mixed integer ROP to derive the optimal protocols that minimize the cumulative tumor size. While our method may be applied to other cancers, in this work we focus on the treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKI). For simplicity, we focus on one particular mode of toxicity arising from TKI therapy, low blood cell counts, in particular low absolute neutrophil count (ANC). We develop optimization methods for locating optimal treatment protocols assuming that the rate of decrease of ANC varies within a given interval. We further investigated the relationship between parameter uncertainty and optimal protocols. Our results suggest that the dosing schedule can significantly reduce tumor size without recurrence in 360 weeks while insuring that toxicity constraints are satisfied for all realizations of uncertain parameters.",
keywords = "Cancer treatment, Mixed integer optimization, Robust optimization, Toxicity uncertainty",
author = "Junfeng Zhu and Hamidreza Badri and Leder, {Kevin Z}",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/978-1-4939-7493-1_15",
language = "English (US)",
series = "Methods in Molecular Biology",
publisher = "Humana Press Inc.",
pages = "297--331",
booktitle = "Methods in Molecular Biology",

}

TY - CHAP

T1 - A robust optimization approach to cancer treatment under toxicity uncertainty

AU - Zhu, Junfeng

AU - Badri, Hamidreza

AU - Leder, Kevin Z

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The design of optimal protocols plays an important role in cancer treatment. However, in clinical applications, the outcomes under the optimal protocols are sensitive to variations of parameter settings such as drug effects and the attributes of age, weight, and health conditions in human subjects. One approach to overcoming this challenge is to formulate the problem of finding an optimal treatment protocol as a robust optimization problem (ROP) that takes parameter uncertainty into account. In this chapter, we describe a method to model toxicity uncertainty. We then apply a mixed integer ROP to derive the optimal protocols that minimize the cumulative tumor size. While our method may be applied to other cancers, in this work we focus on the treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKI). For simplicity, we focus on one particular mode of toxicity arising from TKI therapy, low blood cell counts, in particular low absolute neutrophil count (ANC). We develop optimization methods for locating optimal treatment protocols assuming that the rate of decrease of ANC varies within a given interval. We further investigated the relationship between parameter uncertainty and optimal protocols. Our results suggest that the dosing schedule can significantly reduce tumor size without recurrence in 360 weeks while insuring that toxicity constraints are satisfied for all realizations of uncertain parameters.

AB - The design of optimal protocols plays an important role in cancer treatment. However, in clinical applications, the outcomes under the optimal protocols are sensitive to variations of parameter settings such as drug effects and the attributes of age, weight, and health conditions in human subjects. One approach to overcoming this challenge is to formulate the problem of finding an optimal treatment protocol as a robust optimization problem (ROP) that takes parameter uncertainty into account. In this chapter, we describe a method to model toxicity uncertainty. We then apply a mixed integer ROP to derive the optimal protocols that minimize the cumulative tumor size. While our method may be applied to other cancers, in this work we focus on the treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKI). For simplicity, we focus on one particular mode of toxicity arising from TKI therapy, low blood cell counts, in particular low absolute neutrophil count (ANC). We develop optimization methods for locating optimal treatment protocols assuming that the rate of decrease of ANC varies within a given interval. We further investigated the relationship between parameter uncertainty and optimal protocols. Our results suggest that the dosing schedule can significantly reduce tumor size without recurrence in 360 weeks while insuring that toxicity constraints are satisfied for all realizations of uncertain parameters.

KW - Cancer treatment

KW - Mixed integer optimization

KW - Robust optimization

KW - Toxicity uncertainty

UR - http://www.scopus.com/inward/record.url?scp=85041054397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041054397&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-7493-1_15

DO - 10.1007/978-1-4939-7493-1_15

M3 - Chapter

C2 - 29344896

AN - SCOPUS:85041054397

T3 - Methods in Molecular Biology

SP - 297

EP - 331

BT - Methods in Molecular Biology

PB - Humana Press Inc.

ER -